ScholarIQanswers from OpenAlex & ORCID
Christopher L. Bowlus
ResearcherPublications, citations & collaboration network
Christopher L. Bowlus is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Christopher L. Bowlus have?
ScholarIQindexed works
Christopher L. Bowlus has 434 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Christopher L. Bowlus have?
ScholarIQcitation count
Christopher L. Bowlus has 17,318 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Christopher L. Bowlus?
ScholarIQh-index
Christopher L. Bowlus has an h-index of 72 in OpenAlex.
What is the i10-index of Christopher L. Bowlus?
ScholarIQi10-index
Christopher L. Bowlus has an i10-index of 188 in OpenAlex.
What is the ORCID of Christopher L. Bowlus?
ScholarIQorcid
The ORCID for Christopher L. Bowlus is on the source record.
What is the OpenAlex record for Christopher L. Bowlus?
ScholarIQopenalex
The OpenAlex for Christopher L. Bowlus is on the source record.
What are the most-cited papers on Christopher L. Bowlus?
ScholarIQmost cited works
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens, Pietro Andreoné, G. Mazzella, Simone I. Strasser, Christopher L. Bowlus, Pietro Invernizzi, Joost P.H. Drenth, Paul J. Pockros, Jarosław Reguła, Ulrich Beuers, Michael Trauner, David Jones, Annarosa Floreani, Simon Hohenester, Velimir A. Luketic, Mitchell L. Shiffman, Karel J. van Erpecum, Vı́ctor Vargas, Catherine Vincent, Gideon M. Hirschfield, Hemant Shah, Bettina E. Hansen, Keith D. Lindor, Hanns–Ulrich Marschall, Kris V. Kowdley, Roya Hooshmand-Rad, Tonya Marmon, Shawn Sheeron, Richard Pencek, Leigh MacConell, Mark Pruzanski, Д. А. Шапиро
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
Tobias J. Weismüller, Palak Trivedi, Annika Bergquist, Mohamad Imam, Henrike Lenzen, Cyriel Y. Ponsioen, Kristian Holm, Daniel Gotthardt, Martti Färkkilâ, Hanns–Ulrich Marschall, Douglas Thorburn, Rinse K. Weersma, Johan Fevery, Tobias Mueller, Olivier Chazouillères, Kornelius Schulze, Konstantinos N. Lazaridis, Sven Almér, Stephen P. Pereira, Cynthia Levy, Andrew L. Mason, Sigrid Næss, Christopher L. Bowlus, Annarosa Floreani, Emina Halilbasic, Kidist Yimam, Piotr Milkiewicz, Ulrich Beuers, Dep Huynh, Albert Parés, Christine N. Manser, George Ν. Dalekos, Bertus Eksteen, Pietro Invernizzi, Christoph P. Berg, Gabi I. Kirchner, Christoph Sarrazin, Vincent Zimmer, Luca Fabris, Felix Braun, Marco Marzioni, Brian D. Juran, Karouk Said, Christian Rupp, Kalle Jokelainen, M Valle, Francesca Saffioti, Angela Cheung, Michael Trauner, Christoph Schramm, Roger W. Chapman, Tom H. Karlsen, Erik Schrumpf, Christian P. Strassburg, Michael P. Manns, Keith D. Lindor, Gideon M. Hirschfield, Bettina E. Hansen, Kirsten Muri Boberg
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark Jonas, Andreas E. Kremer, George Mells, Peter Buggisch, B. Freilich, Cynthia Levy, John M. Vierling, David Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. Smith, Yun‐Jung Choi, Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield